"Premier hôpital privé du Val-de-Marne, l'Hôpital privé Paul d'Egine, établissement du groupe Ramsay Santé, dispose de l'ensemble des spécialités chirurgicales ainsi qu'un service de médecine, de dialyse et un service d'urgences ouvert 24h/24. L'établissement est expert en plusieurs domaines : 1er SOS main, cancérologie, chirurgie vasculaire et chirurgie de la colonne vertébrale..."

During the past decade, Hôpital Privé Paul d'Egine conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Privé Paul d'Egine" #1 sponsor was "Centre Francois Baclesse" with 2 trials, followed by "Federation Francophone de Cancerologie Digestive" with 2 trials sponsored, "Ramsay Générale de Santé" with 2 trials sponsored, "Biotronik SE & Co. KG" with 1 trials sponsored and "Boston Scientific Corporation" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Privé Paul d'Egine" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "DePuy Synthes" with 1 trials as a collaborator, "European Clinical Trial Experts Network" with 1 trials as a collaborator and "LDR Médical" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Privé Paul d'Egine" are "Amyloid" (1 trials), "Arterial Occlusive Diseases" (1 trials), "Arteriosclerosis" (1 trials), "Atherosclerosis" (1 trials) and "Auriculotherapy" (1 trials). Many other conditions were trialed in "Hôpital Privé Paul d'Egine" in a lesser frequency.

Most popular intervention types in "Hôpital Privé Paul d'Egine" are "Drug" (4 trials), "Other" (3 trials), "Device" (2 trials), "Behavioral" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Auriculotherapy" (1 trials), "Auriculotherapy for analgesic use" (1 trials), "Bevacizumab" (1 trials), "Capecitabine" (1 trials) and "Chronic Post-Surgical Pain evaluation" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Privé Paul d'Egine" are 10 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Hôpital Privé Paul d'Egine". undefined are not yet recruiting, 7 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Hôpital Privé Paul d'Egine, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Privé Paul d'Egine, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".